ADVERTISEMENT
Concurrent Osimertinib Improved PFS Among Patients With Unresectable, Stage 3 EGFR-Mutated Non-Small Cell Lung Cancer
Suresh Ramalingam, MD, Emory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia, discussed results from the phase 3 LAURA study. Results demonstrated that administration of osimertinib after definitive chemoradiation improved progression-free survival (PFS) among patients with unresectable, stage 3, EGFR-mutated non-small cell lung cancer (NSCLC).
Source:
Ramalingam SS. Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study. Presented at the ASCO Annual Meeting. May 31 – June 4, 2024; Chicago, IL. Abstract LBA4
© 2024 HMP Global. All Rights Reserved.
Any views and opinions expressed are those of the author(s) and/or participants and do not necessarily reflect the views, policy, or position of Oncology Learning Network or HMP Global, their employees, and affiliates.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Visit the OLN Excellence Forums
Advertisement
Advertisement
Advertisement